Table 1 Model transition probabilities [30]
From: Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patients
DTG + TDF/3TC | EFV + TDF/3TCa | LPV/r + TDF/3TCb | |
|---|---|---|---|
Virology suppression | |||
First 11 months | 16.3%a/15.1%b | 12.4% | 10.4% |
Month 12–22 | 0.2% | 0.1% | 0.1% |
After month 22 | 0.0% | 0.0% | 0.0% |
Discontinuation due to failure (first line) | |||
First 11 months | 0.46%a/0.17%b | 0.86% | 0.60% |
Month 12–22 | 0.10%a/0.05%b | 0.08% | 0.04% |
After month 22 | 0.05%a/0.02%b | 0.06% | 0.04% |
Discontinuation with other cause (first line) | |||
First 11 months | 0.55%a/0.63%b | 0.62% | 0.91% |
Month 12–22 | 0.12%a/0.18%b | 0.06% | 0.06% |
After month 22 | 0.06%a/0.08%b | 0.04% | 0.06% |
Discontinuation (second line plus) | |||
First 11 months | 1.03% | 1.54% | 1.54% |
Month 12–22 | 0.23% | 0.10% | 0.10% |
After month 22 | 0.10% | 0.10% | 0.10% |
CD4+ increase | |||
First 11 months | 20.29 | 16.42 | 15.46 |
Month 12–22 | 2.51 | 0.56 | 0.56 |
After month 22 | − 2.32 | − 2.32 | − 2.32 |